![Manuel A. Navia](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Manuel A. Navia
Corporate Officer/Principal chez
AdipoGenix, Inc.
Profil
Manuel A. Navia is the founder of Althexis Co., Inc. (founded in 1997) and Altus Pharmaceuticals, Inc. (founded in 1992).
He held the title of President & Chief Executive Officer at Althexis Co., Inc. in 2001 and was a Director at Altus Pharmaceuticals, Inc. Dr. Navia's current job was as a Member-Advisory Board at AdipoGenix, Inc. since 2011.
Dr. Navia's former jobs include being a Vice President & Senior Scientist at Vertex Pharmaceuticals, Inc. from 1989 to 1997, and an Executive Vice President-Research at Essential Therapeutics, Inc. from 2001 to 2003.
He also served as an Executive-in-Residence at Oxford Bioscience Partners and as a Strategic Advisor at Access BridgeGap Ventures.
Dr. Navia's education includes a graduate and doctorate degree from The University of Chicago, and an undergraduate degree from New York University.
Postes actifs de Manuel A. Navia
| Sociétés | Poste | Début |
|---|---|---|
AdipoGenix, Inc.
 AdipoGenix, Inc. Pharmaceuticals: MajorHealth Technology Develops molecular pharmaceutical products | Corporate Officer/Principal | 23/05/2011 |
Anciens postes connus de Manuel A. Navia
| Sociétés | Poste | Fin |
|---|---|---|
Access BridgeGap Ventures
 Access BridgeGap Ventures Investment ManagersFinance Access Bridgegap Ventures seeks to bridge the early-stage investment gap in the therapeutics space. The firm leverages their experience in start-up creation, technology commercialization and venture investing to fund young start-ups and create de novo spin-offs around potential high-impact technologies, many of which are still in academic research labs. | Corporate Officer/Principal | 10/10/2013 |
Essential Therapeutics, Inc.
 Essential Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical goods for viral and fungal infections | Directeur Technique/Scientifique/R&D | 01/03/2003 |
Althexis Co., Inc.
 Althexis Co., Inc. Miscellaneous Commercial ServicesCommercial Services Researches and develops drugs for the treatment of human diseases | Fondateur | 01/01/2001 |
| VERTEX PHARMACEUTICALS INCORPORATED | Corporate Officer/Principal | 01/01/1997 |
Altus Pharmaceuticals, Inc.
 Altus Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops therapeutic products for gastrointestinal and metabolic diseases | Fondateur | - |
Formation de Manuel A. Navia
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
31
Relations au 1er degré
9
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 9 |
|---|---|
Vertex Pharmaceuticals, Inc.
 Vertex Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company that develops drugs for the treatment of cystic fibrosis | Health Technology |
Essential Therapeutics, Inc.
Essential Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical goods for viral and fungal infections | Health Technology |
Oxford Bioscience Partners
 Oxford Bioscience Partners Investment ManagersFinance Oxford Bioscience Partners (OBP) focuses on investments in emerging, entrepreneurial-driven companies in the life sciences and healthcare sectors. They look for companies in the medical devices, R&D instruments and systems and therapeutics industries and for companies with breakthrough life sciences technology. The firm also invests in non-life science based technologies that have novel healthcare applications. OBP considers investments at almost any stage, but they place emphasis on early-stage opportunities. Investments range from $1 million to $10 million, but they may also make smaller seed investments in certain situations. OBP acts as the lead investor to organize an appropriate syndicate of co-investors. They consider investments in almost all geographic locations. | Finance |
AdipoGenix, Inc.
AdipoGenix, Inc. Pharmaceuticals: MajorHealth Technology Develops molecular pharmaceutical products | Health Technology |
Althexis Co., Inc.
Althexis Co., Inc. Miscellaneous Commercial ServicesCommercial Services Researches and develops drugs for the treatment of human diseases | Commercial Services |
The University of Chicago
 The University of Chicago Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
New York University
 New York University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Altus Pharmaceuticals, Inc.
Altus Pharmaceuticals, Inc. BiotechnologyHealth Technology Develops therapeutic products for gastrointestinal and metabolic diseases | Health Technology |
Access BridgeGap Ventures
Access BridgeGap Ventures Investment ManagersFinance Access Bridgegap Ventures seeks to bridge the early-stage investment gap in the therapeutics space. The firm leverages their experience in start-up creation, technology commercialization and venture investing to fund young start-ups and create de novo spin-offs around potential high-impact technologies, many of which are still in academic research labs. | Finance |
